Core Insights - Insmed Incorporated is set to present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026, at 3:00 p.m. PT / 6:00 p.m. ET [1] - The presentation will be available via a live webcast on the company's investor relations website, with an archive accessible for 30 days post-event [2] Company Overview - Insmed is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for patients with serious diseases [3] - The company has a diverse portfolio that includes approved and mid- to late-stage investigational medicines, particularly in pulmonary and inflammatory conditions, with two approved therapies for chronic lung diseases [3] - Insmed's early-stage programs utilize various advanced technologies, including gene therapy, AI-driven protein engineering, and synthetic rescue [3] - Headquartered in Bridgewater, New Jersey, Insmed operates research locations across the U.S., Europe, and Japan, and has been recognized as a top employer in the biopharmaceutical industry [4]

Core Viewpoint - Insmed Incorporated will release its second-quarter 2025 financial results on August 7, 2025, and will host a conference call for investors to discuss these results and provide a business update [1][2]. Company Overview - Insmed is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for patients with serious diseases, with a diverse portfolio of approved and investigational medicines [4]. - The company is advancing programs primarily in pulmonary and inflammatory conditions, including a therapy approved in the U.S., Europe, and Japan for a chronic lung disease [4]. - Insmed's early-stage programs involve various technologies such as gene therapy, AI-driven protein engineering, and synthetic rescue [4]. Conference Call Details - The conference call for investors will begin at 8:00 a.m. ET on August 7, 2025, and can be accessed via phone or webcast [2]. - A replay of the conference call will be available approximately one hour after its completion until August 14, 2025 [3].

Company Overview - Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for patients with serious diseases [3][4] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [3] - Insmed's early-stage programs include various technologies such as gene therapy, AI-driven protein engineering, and synthetic rescue [3] Upcoming Event - Management will present at the 2025 Goldman Sachs Annual Global Healthcare Conference on June 11, 2025, at 9:20 a.m. ET [1] - The event will be webcast live and available for 30 days post-event on the company's investor relations website [2]